Achalasia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Achalasia Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Achalasia is a rare diseased condition where the lower esophageal sphincter (LES) muscle fails to function properly during swallowing of food. The exact cause of achalasia is unknown. Complications include the absence of contractions also known as peristalsis leading to difficulty in swallowing and chest pain. This is due to the degeneration of esophageal muscles and the nerves which control these muscles. Other complications may include lung problems and weight loss.
The report provides achalasia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. among others.
Scope:
Achalasia Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Achalasia is a rare diseased condition where the lower esophageal sphincter (LES) muscle fails to function properly during swallowing of food. The exact cause of achalasia is unknown. Complications include the absence of contractions also known as peristalsis leading to difficulty in swallowing and chest pain. This is due to the degeneration of esophageal muscles and the nerves which control these muscles. Other complications may include lung problems and weight loss.
The report provides achalasia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. among others.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction
2. Disease Overview
4. Market Dynamics
5. Pipeline Analysis/Outlook
6. Company profiling
Companies Mentioned
- Astellas Pharma Inc.
- Ironwood Pharmaceuticals, Inc.
- Ipsen
- Cernostics
Methodology
LOADING...
